Shares of Novavax, Inc. (NASDAQ:NVAX) saw unusually-high trading volume on Monday after an insider bought additional shares in the company. Approximately 2,289,400 shares were traded during mid-day trading, a decline of 35% from the previous session’s volume of 3,506,179 shares.The stock last traded at $1.12 and had previously closed at $1.13.
Specifically, Director James F. Young sold 175,000 shares of the firm’s stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $1.06, for a total transaction of $185,500.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Stanley C. Erck purchased 100,000 shares of the business’s stock in a transaction dated Thursday, November 9th. The shares were purchased at an average price of $1.13 per share, for a total transaction of $113,000.00. Following the purchase, the insider now owns 228,279 shares of the company’s stock, valued at approximately $257,955.27. The disclosure for this purchase can be found here. 4.00% of the stock is currently owned by company insiders.
Several equities analysts have issued reports on NVAX shares. Cantor Fitzgerald reiterated a “hold” rating and issued a $2.00 target price on shares of Novavax in a research note on Friday, July 21st. BidaskClub lowered Novavax from a “hold” rating to a “sell” rating in a research note on Wednesday, July 19th. Seaport Global Securities reiterated a “neutral” rating on shares of Novavax in a research note on Friday, October 6th. Zacks Investment Research lowered Novavax from a “buy” rating to a “hold” rating in a research note on Wednesday, July 26th. Finally, Piper Jaffray Companies reiterated a “hold” rating and issued a $1.50 target price on shares of Novavax in a research note on Wednesday, July 26th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and three have issued a buy rating to the company. Novavax currently has a consensus rating of “Hold” and an average target price of $3.12.
Novavax (NASDAQ:NVAX) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.01. Novavax had a negative return on equity of 787.38% and a negative net margin of 726.35%. The firm had revenue of $8.35 million during the quarter, compared to the consensus estimate of $6.42 million. During the same quarter in the previous year, the company posted ($0.24) earnings per share. The company’s revenue was up 158.5% compared to the same quarter last year. research analysts predict that Novavax, Inc. will post -0.61 EPS for the current fiscal year.
Large investors have recently made changes to their positions in the business. Raymond James Financial Services Advisors Inc. lifted its holdings in Novavax by 49.8% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 89,697 shares of the biopharmaceutical company’s stock valued at $103,000 after acquiring an additional 29,800 shares during the period. Profund Advisors LLC lifted its holdings in Novavax by 0.4% in the second quarter. Profund Advisors LLC now owns 120,775 shares of the biopharmaceutical company’s stock valued at $139,000 after acquiring an additional 455 shares during the period. Voya Investment Management LLC lifted its holdings in Novavax by 18.6% in the second quarter. Voya Investment Management LLC now owns 138,270 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 21,639 shares during the period. HighTower Advisors LLC lifted its holdings in Novavax by 3.8% in the first quarter. HighTower Advisors LLC now owns 142,000 shares of the biopharmaceutical company’s stock valued at $184,000 after acquiring an additional 5,250 shares during the period. Finally, Brown Advisory Inc. lifted its holdings in Novavax by 74.8% in the third quarter. Brown Advisory Inc. now owns 162,700 shares of the biopharmaceutical company’s stock valued at $185,000 after acquiring an additional 69,600 shares during the period. 38.87% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: “Novavax, Inc. (NVAX) Sees Strong Trading Volume on Insider Buying Activity” was published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.themarketsdaily.com/2017/11/14/novavax-inc-nvax-sees-strong-trading-volume-on-insider-buying-activity.html.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
Receive News & Ratings for Novavax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.